Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ 1,103	$ (20)
Adjustments to reconcile net income (loss) to net cash flows from operating activities:
(Gains) losses on marketable securities, net	(699)	1,257
Depreciation and amortization	1,063	1,022
Allowance for equity funds	(49)	(38)
Equity (income) loss, net of distributions	68	88
Net power cost deferrals	(504)	(72)
Amortization of net power cost deferrals	130	47
Other changes in regulatory assets and liabilities	(26)	(17)
Deferred income taxes and investment tax credits, net	(11)	(203)
Other, net	15	6
Changes in other operating assets and liabilities, net of effects from acquisitions:
Trade receivables and other assets	120	333
Derivative collateral, net	(225)	85
Pension and other postretirement benefit plans	(7)	(11)
Accrued property, income and other taxes, net	(177)	(347)
Accounts payable and other liabilities	294	91
Net cash flows from operating activities	1,095	2,221
Cash flows from investing activities:
Capital expenditures	(1,848)	(1,553)
Purchases of marketable securities	(106)	(170)
Proceeds from sales of marketable securities	1,091	149
Purchases of U.S. Treasury Bills	(1,519)	0
Proceeds from maturities of U.S. Treasury Bills	623	0
Equity method investments	(19)	(17)
Other, net	0	19
Net cash flows from investing activities	(1,778)	(1,572)
Cash flows from financing activities:
Repayments of BHE senior debt	(400)	0
Proceeds from subsidiary debt	0	405
Repayments of subsidiary debt	(136)	(193)
Net proceeds from (repayments of) short-term debt	699	(165)
Distributions to noncontrolling interests	(126)	(117)
Other, net	(17)	(240)
Net cash flows from financing activities	20	(310)
Effect of exchange rate changes	1	(1)
Net change in cash and cash equivalents and restricted cash and cash equivalents	(662)	338
Cash and cash equivalents and restricted cash and cash equivalents at beginning of period	1,817	1,244
Cash and cash equivalents and restricted cash and cash equivalents at end of period	$ 1,155	$ 1,582